New DNA H1N1 Vaccine Currently in Clinical Trials
CNN.com points to the vaccine as one of the top medical innovations of the year, highlighting its rapid development. In a recent advance, the National Institute of Allergy and Infectious Diseases (NIAID) has started clinical trials of a DNA vaccine for H1N1. These vaccine—that inject genetic material from the virus into patients—may be faster to produce and provide cross-protection against other viruses.
Vaccine Delays Affected Delivery
News and commentary on vaccine shortages and delays in delivery also made news. The Chicago Daily Herald called the H1N1 pandemic a test of the country’s public health emergency system. According to the article ("Swine Flu''s Lesson: We''re Not Ready for Anything Virulent," Dec. 14) some critics say that the vaccine was not rolled out quickly enough to get it to those who needed it most.
The San Francisco Chronicle reported that distribution problems for the vaccine forced the state of California to reevaluate its plans for vaccine implementation ("Distribution Plans Fall Short for H1N1 Vaccine," Dec. 14). Unexpected vaccine shortages sent state and local health officials scrambling to make the vaccine available to those who needed it most.